Abstract
No public abstract is available from the verified source records.
Florestan Johannes Koll, Robin Sebastian Mayer, Marcel H. Schulz, Felix H. K. Chun, Markus Eckstein, Anne Fassl, Jens W. Köllermann, Peter J. Wild
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unresolved referenced work
Kept as external metadata until matched
Characteristics, treatment patterns, and clinical outcomes of patients undergoing neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer in the real world
10.1200/jco.2024.42.4_suppl.552 · 2024
Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants
10.1016/j.eururo.2018.09.003 · 2018
Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer
10.1158/1078-0432.ccr-18-1106 · 2018
Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
10.1016/j.ccr.2014.01.009 · 2014
Assessment of luminal and basal phenotypes in bladder cancer
10.1038/s41598-020-66747-7 · 2020
Clinical implications of molecular subtyping in bladder cancer
10.1097/mou.0000000000000641 · 2019
Impact of consensus molecular subtypes on survival with and without adjuvant chemotherapy in muscle-invasive urothelial bladder cancer
2023
A consensus molecular classification of muscle-invasive bladder cancer
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
pubmed
Confidence 98%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1016/j.eururo.2019.09.006 · 2019
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
10.1038/s41591-019-0462-y · 2019
Deep learning based on hematoxylin–eosin staining outperforms immunohistochemistry in predicting molecular subtypes of gastric adenocarcinoma
10.1002/path.5879 · 2022
Real-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detection
10.1038/s41591-025-03780-x · 2025
Deep Learning Predicts Molecular Subtype of Muscle-invasive Bladder Cancer from Conventional Histopathological Slides
10.1016/j.eururo.2020.04.023 · 2020
Classification and mutation prediction based on histopathology H&E images in liver cancer using deep learning
10.1038/s41698-020-0120-3 · 2020
A deep learning model to predict RNA-Seq expression of tumours from whole slide images
10.1038/s41467-020-17678-4 · 2020
Deep learning predicts gene expression as an intermediate data modality to identify susceptibility patterns in Mycobacterium tuberculosis infected Diversity Outbred mice
10.1016/j.ebiom.2021.103388 · 2021
Predicting Molecular Phenotypes from Histopathology Images: A Transcriptome-Wide Expression–Morphology Analysis in Breast Cancer
10.1158/0008-5472.can-21-0482 · 2021
Surrogate Biomarker Prediction from Whole-Slide Images for Evaluating Overall Survival in Lung Adenocarcinoma
10.3390/diagnostics14050462 · 2024
Transformer-based unsupervised contrastive learning for histopathological image classification
10.1016/j.media.2022.102559 · 2022
A foundation model for clinical-grade computational pathology and rare cancers detection
10.1038/s41591-024-03141-0 · 2024
A whole-slide foundation model for digital pathology from real-world data
10.1038/s41586-024-07441-w · 2024
Method for diagnosis of acute lymphoblastic leukemia based on VIT‐CNN Ensemble model
10.1155/2021/7529893 · 2021
Plant-CNN-ViT: Plant Classification with Ensemble of Convolutional Neural Networks and Vision Transformer
10.3390/plants12142642 · 2023
Vision Transformer-Based Ensemble Learning for hyperspectral image classification
10.3390/rs15215208 · 2023
Comprehensive molecular characterization of Muscle-Invasive Bladder Cancer
10.1016/j.cell.2017.09.007 · 2017
Histomolekulare Klassifikation des Urothelkarzinoms der Harnblase
10.1007/s00292-024-01305-w · 2024
Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: a comparison of two sequencing methods and gene sets using FFPE specimens
10.1186/s12885-023-11016-9 · 2023
ACAT: A Fast and Powerful p Value Combination Method for Rare-Variant Analysis in Sequencing Studies
10.1016/j.ajhg.2019.01.002 · 2019
Molecular urothelial tumor cell subtypes remain stable during metastatic evolution
10.1016/j.eururo.2023.03.020 · 2023
NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer
10.1200/jco.23.01983 · 2024
TROP2 expression across molecular subtypes of urothelial carcinoma and enfortumab vedotin-resistant cells
10.1016/j.euo.2021.11.005 · 2022
Concordance and prognostic value of antibody drug conjugate and checkpoint inhibition targets in matched bladder cancer specimens from transurethral resection of the bladder, radical cystectomy and lymphadenectomy
10.1016/j.urolonc.2026.111095 · 2026
Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy
10.1016/j.ejca.2021.01.036 · 2021
CXCL10 could be a prognostic and immunological biomarker in bladder cancer
10.1007/s12672-024-00982-6 · 2024
Upregulation of IFNɣ-mediated chemokines dominate the immune transcriptome of muscle-invasive urothelial carcinoma
10.1038/s41598-021-04678-7 · 2022
Artificial intelligence meets whole slide images: deep learning model shapes an Immune-Hot tumor and guides precision therapy in bladder cancer
2022
Overexpression of HMGA2 in bladder cancer and its association with clinicopathologic features and prognosis
10.1016/j.ejso.2011.01.004 · 2011
Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy
10.1016/j.urolonc.2012.06.011 · 2012
Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression
10.1111/j.1440-1827.2010.02592.x · 2010
CD44 in bladder cancer
10.3390/cancers16061195 · 2024
Living in a noisy world—origins of gene expression noise and its impact on cellular decision‐making
10.1002/1873-3468.14898 · doi-reference
Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning
10.1136/gutjnl-2019-319866 · doi-reference
Learning latent space representations to predict patient outcomes: model development and validation
10.2196/16374 · doi-reference
Using machine learning to predict laboratory test results
10.1093/ajcp/aqw064 · doi-reference
Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer
10.1038/s41379-021-00911-w · doi-reference
Deep-learning-based HER2 status assessment from multimodal breast cancer data predicts neoadjuvant therapy response
10.1038/s41551-025-01495-5 · doi-reference
In Silico Prediction of Human Clinical Pharmacokinetics with ANDROMEDA by Prosilico: Predictions for an Established Benchmarking Data Set, a Modern Small Drug Data Set, and a Comparison with Laboratory Methods
10.1177/02611929221148447 · doi-reference
Identification of signature genes associated with invasiveness and the construction of a prognostic model that predicts the overall survival of bladder cancer
10.3389/fgene.2021.694777 · doi-reference
Blocking YAP1–Liprin-β2 interaction impedes metastasis and promotes tumor suppression in head and neck squamous carcinoma
10.1038/s41598-025-11652-0 · doi-reference
Identification of ELF3 as an early transcriptional regulator of human urothelium
10.1016/j.ydbio.2013.12.028 · doi-reference
WNT7B represses epithelial-mesenchymal transition and stem-like properties in bladder urothelial carcinoma
10.1016/j.bbadis.2021.166271 · doi-reference
E74 like ETS transcription factor 3 (ELF3) is a negative regulator of epithelial- mesenchymal transition in bladder carcinoma
10.3233/cbm-190013 · doi-reference
High-resolution transcriptome atlas of bladder cancer highlights the functional myeloid subsets in modulating immune microenvironment
10.1016/j.ebiom.2025.105801 · doi-reference
SWI/SNF chromatin remodeling complex and glucose metabolism are deregulated in advanced bladder cancer
10.1002/iub.2254 · doi-reference
Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification
10.1186/s12885-019-6042-1 · doi-reference
Benchmarking the translational potential of spatial gene expression prediction from histology
10.1038/s41467-025-56618-y · doi-reference
Digital profiling of gene expression from histology images with linearized attention
10.1038/s41467-024-54182-5 · doi-reference
Accurate Diagnosis and Survival Prediction of Bladder Cancer Using Deep Learning on Histological Slides
10.3390/cancers14235807 · doi-reference
Efficacy and safety of trastuzumab deruxtecan in patients with HER2-Expressing solid tumors: Primary results from the DESTINY-PanTumor02 Phase II trial
10.1200/jco.23.02005 · doi-reference
Ensemble learning using decorrelated neural networks
10.1080/095400996116820 · doi-reference
Benchmarking foundation models as feature extractors for weakly supervised computational pathology
10.1038/s41551-025-01516-3 · doi-reference
Comparing two correlated C indices with right‐censored survival outcome: a one‐shot nonparametric approach
10.1002/sim.6370 · doi-reference
FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy
10.3390/jcm9040994 · doi-reference
Loss of FOXA1 drives sexually dimorphic changes in urothelial differentiation and is an independent predictor of poor prognosis in bladder cancer
10.1016/j.ajpath.2015.01.014 · doi-reference
FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of Castration-Resistant prostate cancer
10.1016/j.ajpath.2011.10.021 · doi-reference
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
10.1038/ng.2279 · doi-reference
FBP1 regulates proliferation, metastasis, and chemoresistance by participating in C-MYC/STAT3 signaling axis in ovarian cancer
10.1038/s41388-021-01957-5 · doi-reference
Snai2‐mediated upregulation of NADSYN1 promotes bladder cancer progression by interacting with PHB
10.1002/ctm2.1555 · doi-reference
The urothelial gene regulatory network: understanding biology to improve bladder cancer management
10.1038/s41388-023-02876-3 · doi-reference
PPARγ activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway
10.1186/s12885-019-5426-6 · doi-reference
FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation
10.1038/s41467-022-34251-3 · doi-reference